T细胞输注治疗造血干细胞移植后病毒感染：第55届美国血液学会年会报道

T-cell therapy for viral infections after hematopoietic stem cell transplantation in the 55th ASH annual meeting

在免疫缺陷的患者如造血干细胞移植（HSCT）患者中,病毒感染已成为死亡的主要原因.来自于供者的病毒特异性细胞毒性T淋巴细胞（CTL）输注已成为重建病毒免疫的一个方法,CTL能够预防及治疗病毒感染性疾病,在临床上已有超过20年的使用经验.第55届美国血液学会（ASH）年会报道了关于制备、应用CTL的基础及临床试验,并且总结了大量评估其疗效的试验,为将来治疗HSCT后病毒感染提供了新思路.

Viral infections remain a major cause of morbidity in patients with immunodeficiency,such as recipients of hematopoietic stem cell transplantation （HSCT）.Adoptive transfer of donor-derived virusspecific cytotoxic T lymphocytes is a strategy to restore virus-specific immunity to prevent or treat viral diseases and has been tested in the clinical setting for more than 20 years.The 55th ASH annual meeting reported lots of basic and clinical experience about CTL and summarized lots of trails to evaluate it,which will give us some new thought about the antivirus therapy after HSCT.